Welcome to our dedicated page for Dogecoin Cash news (Ticker: CBDS), a resource for investors and traders seeking the latest updates and insights on Dogecoin Cash stock.
Cannabis Sativa Inc (CBDS) combines herbal wellness innovation with blockchain technology, operating at the intersection of natural products and digital asset strategies. This news hub provides investors and industry observers with verified updates on the company's dual focus areas.
Access timely announcements covering new product launches in herbal skincare, cannabis telemedicine developments through Presto Doctor, and blockchain integration initiatives. The repository includes earnings reports, regulatory filings, partnership announcements, and technology updates from CBDS subsidiaries like Wild Earth Naturals and iBuddTender.
Bookmark this page for structured access to CBDS's latest operational milestones, including patent filings, digital asset acquisitions, and market expansion efforts. All content is sourced from official company communications to ensure compliance with financial disclosure standards.
Dogecoin Cash (OTCIQ: CBDS) subsidiary PrestoDoctor announces its largest-ever discount promotion for April 2025, offering 42.0% off medical cannabis card evaluations and renewals. The promotion, celebrating the cultural cannabis date 4/20, is available to both new and returning patients in participating states through PrestoDoctor's HIPAA-compliant telemedicine platform.
Through the company's digital platform, patients can schedule same-day appointments for video consultations with licensed physicians, receiving immediate digital recommendations and official documentation by mail. The service emphasizes accessibility and convenience in obtaining medical cannabis evaluations.
Dogecoin Cash (OTC: CBDS) has announced that its subsidiary, MEME Coins Inc., has entered into a definitive agreement with Tipestry, Inc. to acquire 1 billion Dogecoin Cash (DOG) tokens. The deal involves MEME Coins Inc. issuing 500,000 preferred shares valued at $20.00 each to Tipestry in exchange for the tokens.
This marks MEME Coins' third DOG acquisition, bringing their total holdings to 2.02 billion DOG tokens. The agreement, executed on March 12, 2025, involves no dilution to existing common shareholders of Dogecoin Cash. The transaction will be completed upon mutual fulfillment of obligations and is governed by Colorado state laws.
CBDS operates PrestoDoctor, a medical cannabis telemedicine platform, and holds patents for an Ecuadorian Sativa cannabis strain and a hypertension treatment lozenge. The company focuses on cannabis product development, telemedicine, and blockchain innovation.
Dogecoin Cash ($CBDS) has announced its expansion into the meme coin market through the formation of a new subsidiary, MEME COINS Inc. The company aims to capitalize on the growing meme coin trend while protecting shareholder equity through a strategic approach that avoids dilution.
The subsidiary will focus on three main strategies:
- Developing proprietary meme coins with real-world applications
- Partnering with influencers for viral marketing
- Creating a community-first ecosystem for trading and governance
MEME COINS Inc. will raise funds through preferred shares rather than common stock to maintain current equity positions. The subsidiary plans to acquire established meme coins like Dogecoin and invest in new projects with strong community engagement. The company cites the recent success of high-profile meme coin launches and the market's billions in daily trading volume as key drivers for this strategic expansion.
Dogecoin Cash (OTCQB: CBDS) has announced a definitive agreement with Bots, Inc. (BTZI) to acquire 420 million DogeCoin Cash ($DOG) tokens in exchange for 4.2 million shares of CBDS common stock. The transaction is set to close on March 1, 2025, with CBDS establishing a Binance Wallet for the token transfer.
This acquisition follows CBDS's previous purchase of 600 million $DOG from DogeSPAC, Upon completion, CBDS's total $DOG holdings will reach 1.02 billion tokens. The agreement with Bots, Inc. represents a transfer of 50% of their $DOG holdings, which currently total 840 million tokens.
The company also provided an update regarding its preferred dividend, indicating that FINRA is not expected to set an ex-dividend date, meaning only shareholders who held common shares on November 25, 2024, will likely receive the preferred shares.
Cannabis Sativa, Inc. (OTCQB:CBDS) announced that PrestoDoctor will conduct on-site medical cannabis evaluations at the 9th annual Pennsylvania Cannabis Festival, Pocono 420, at Pocono Raceway on April 22-23. COO Rob Tankson emphasized the ease of the medical evaluation process during the event, which integrates proprietary technology for a streamlined experience while ensuring privacy. PrestoDoctor has successfully hosted over 100 similar events. The festival will feature numerous vendors, food trucks, panels, music, and infield camping. PrestoDoctor is recognized as the top online medical marijuana doctor service and operates in multiple states. The company is engaged in telehealth and cannabis-related intellectual property. The press release also includes forward-looking statements and highlights potential risks involved in the cannabis industry.
Cannabis Sativa, Inc. (OTCQB:CBDS) announces the expansion of PrestoDoctor, its leading telemedicine service, to Louisiana, providing patients with access to online medical cannabis cards. With over 100,000 patients served across nine states, PrestoDoctor aims to enhance patient care by connecting them to licensed medical doctors for evaluations. CEO David Tobias anticipates substantial appointment growth and increased revenue from this launch, emphasizing the convenience and safety of their proprietary online service.
Cannabis Sativa (OTCQB:CBDS) announced that PrestoDoctor is now offering online medical cannabis card services in Texas. The COO, Rob Tankson, emphasized the service's accessibility for patients, while CEO David Tobias highlighted the potential for increased patient appointments and revenue. Established in 2015, PrestoDoctor has served over 100,000 patients across eight states and is praised for its patient satisfaction, holding more than 18,000 5-star reviews. The company is committed to providing compassionate care and education through telemedicine.
